Medical breakthrough... Vaccine designed to reduce skin cancer recurrence by 42 percent

Lebanon 24: Results from the third phase of an international clinical trial showed that the first vaccine specifically designed using “mRNA” technology against skin cancer reduced the risk of melanoma recurrence or death by 42% when added to standard immunotherapy, a result that exceeded researchers’ expectations. The trial’s lead researcher presented the results,…